|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Agent 4/26/18 Dr Reddys Laboratories Ltd 6-K 4/25/18 2:105K DataTracks Svcs Ltd/FA |
Document/Exhibit Description Pages Size 1: 6-K Current Report by a Foreign Private Issuer HTML 11K 2: EX-99.1 Miscellaneous Exhibit HTML 18K
Exhibit 99.1
 |
Dr. Reddy’s Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, India. CIN : L85195TG1984PLC004507
Tel : +91 40 4900 2900 Fax : +91 40 4900 2999 Email : mail@drreddys.com |
| Corporate Relationship Department | National Stock Exchange of India Ltd. |
| BSE Limited | “Exchange Plaza” |
| Dalal Street, Fort | Bandra-Kurla Complex, Bandra (East), |
| Mumbai – 400 001 | Mumbai – 400 051 |
| Fax Nos.: 022-22723121 / 22723719 / | Fax Nos.: 022-26598120/ 26598237/ |
| 22722037 / 22722039 | 26598238 |
| Scrip Code: 500124 | Scrip Code: DRREDDY-EQ |
Dear Sirs,
Sub: Press Release
Please find enclosed a Press Release on “Dr. Reddy's to release Q4 and full year FY18 results on May 22, 2018, Earnings call slated for May 22, 6:30 PM IST / 9:00 AM EDT”.
This is for your information.
With regards,
| /s/ Sandeep Poddar | |
| Sandeep Poddar | |
| Company Secretary |
CC:- New York Stock Exchange Inc.(Stock Code: RDY)
C:
| CONTACT | ||
| DR. REDDY'S LABORATORIES LTD. | Investor relationS | Media relationS |
|
8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500034. Telangana, India. |
SAUNAK SAVLA saunaks@drreddys.com (Ph: +91-40-49002135) |
Calvin
Printer calvinprinter@drreddys.com (Ph: +91-40- 49002121) |
Dr. Reddy's to release Q4 and full year FY18 results on May 22, 2018
Earnings call slated for May 22, 6:30 PM IST / 9:00 AM EDT
Hyderabad, India, April 25, 2018
Dr. Reddy's Laboratories (BSE: 500124, NSE: DRREDDY, NYSE: RDY) will announce results for the Fourth Quarter and Full year ended March 31, 2018 on Tuesday, May 22, 2018 after the Board Meeting. The results will be available on the Company’s website www.drreddys.com
Summary of Events
| Event | Date and Time | Medium | ||
| Release of financial results | May 22nd, after the Board Meeting | Email, Media, Company website, Business wire | ||
| Earnings Call | May 22nd, 6:30 PM IST / 9:00 AM EDT |
Hosted by the Company (Details below) | ||
| Webcast of Earnings Call | May 22nd, 6:30 PM IST / 9:00 AM EDT through May 28th | URL available on Company’s website, www.drreddys.com | ||
| Transcript of the Earnings call | Will be available on the Company’s website | URL available on Company’s website, www.drreddys.com | ||
| Press meet presentation | Will be available on the Company’s website | URL available on Company’s website, www.drreddys.com |
Earnings Call
Following the release, the management of the Company will host an earnings call to discuss the Company’s financial performance. (Dial In and other details given below)
Audio Webcast
The audio webcast of the earnings call will be available to all interested parties at www.drreddys.com. Please visit the web site at least fifteen minutes ahead of the scheduled start time to register and to download and install any necessary audio software. Participants in the webcast can listen to the proceedings, but will not be able to ask questions. The replay will be available 2 hours after the earnings call, through May 28th, 2018. For play back dial in phone No: 022 7194 5757 / 022 6181 3322, and ID: 375#.
C:
Conference Dial-In Numbers
| Primary Number: | +91 22 6280 1219 |
| Secondary Number: | +91 22 7115 8120 |
The numbers listed above are universally accessible from all networks and all countries.
| Local Access Number: |
Available all over India +91 70456 71221 |
| International Toll Free Number: |
USA: 1 866 746 2133 UK: 0 808 101 1573 Singapore: 800 101 2045 Hong Kong: 800 964 448 |
No password/pin number is necessary to dial in to any of the other calls. As participation in the call is limited, early registration is encouraged. The operator will provide instructions on asking questions before and during the call.
About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr Reddy’s operates in markets across the globe. Our Major markets include – USA, India, Russia & CIS countries, and Europe. For more information, log on to: www.drreddys.com
Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management’s current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words "may", "will", "should", "expects", "plans", "intends", "anticipates", "believes", "estimates", "predicts", "potential", or "continue" and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults , currency exchange rates , interest rates , persistency levels and frequency / severity of insured loss events (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization , including related integration issues.
The company assumes no obligation to update any information contained herein.
C:
| This ‘6-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| 5/22/18 | ||||
| Filed on: | 4/26/18 | |||
| For Period End: | 4/25/18 | 6-K | ||
| 3/31/18 | ||||
| List all Filings | ||||